Halozyme Therapeutics (HALO) EBIT (2010 - 2026)
Halozyme Therapeutics (HALO) recorded EBIT of $287.65 million in Q2 2026, up 42.1% from $202.44 million a year earlier and up 55.9% from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) EBIT (2010 - 2026) Analysis & Trends
On a TTM basis, Halozyme Therapeutics' EBIT came in at $597.2 million as of Jun 30, 2026, down 12.5% year-over-year; for FY2025, it was $469.01 million, down 15.0% from FY2024.
- Annual EBIT has a five-year compound annual growth rate of 26.6% (FY2020 to FY2025).
- Across earlier years, EBIT came in at $551.48 million in FY2024 (+63.4%), $337.57 million in FY2023 (+26.2%), $267.53 million in FY2022 (-3.0%) and $275.9 million in FY2021 (+91.3%).
- The Q2 2026 figure is the highest quarterly EBIT in data going back to Q2 2010.
- Peak year-over-year performance for EBIT in the last five years was growth of 177.3% in Q2 2023, against a decline of 63.4% in Q2 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $184.52 million (Q1 2026), -$92.89 million (Q4 2025) and $217.92 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 1.25 Bn |
| 10 | Halozyme Therapeutics | 12.72 Bn | 11.33 Bn | 401.83 Mn | 287.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 287.65 Mn |
| Mar 31, 2026 | 184.52 Mn |
| Dec 31, 2025 | -92.89 Mn |
| Sep 30, 2025 | 217.92 Mn |
| Jun 30, 2025 | 202.44 Mn |
| Mar 31, 2025 | 141.54 Mn |
| Dec 31, 2024 | 175.50 Mn |
| Sep 30, 2024 | 163.20 Mn |
| Jun 30, 2024 | 117.24 Mn |
| Mar 31, 2024 | 95.54 Mn |
| Dec 31, 2023 | 101.04 Mn |
| Sep 30, 2023 | 88.28 Mn |
| Jun 30, 2023 | 94.46 Mn |
| Mar 31, 2023 | 53.80 Mn |
| Dec 31, 2022 | 74.51 Mn |
| Sep 30, 2022 | 83.29 Mn |
| Jun 30, 2022 | 34.06 Mn |
| Mar 31, 2022 | 75.67 Mn |
| Dec 31, 2021 | 56.53 Mn |
| Sep 30, 2021 | 75.59 Mn |
API Access
Halozyme Therapeutics EBIT API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();